Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS-1 ianalumab in active Sjögren’s syndrome
2024-511069-12-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing ianalumab with placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI score. Started Jul 2024; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-511069-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511069-12-00.